Overview And Clinical Rationale

  • Pediatric tuberculosis is characteristically paucibacillary (low bacterial load, rarely cavitary, predominantly smear-negative) with pathology driven primarily by the host immune response rather than extensive mycobacterial multiplication.
  • Historically, children were treated with standard 6-month adult regimens designed for cavitary, multibacillary adult pulmonary disease—leading to unnecessary drug exposure, pill fatigue, high rates of default, and preventable hepatotoxicity.
  • The SHINE Trial Evidence: Demonstrated that a 4-month (16-week) regimen (2HRZ/2HR) is non-inferior to the conventional 6-month regimen for pediatric non-severe, drug-susceptible tuberculosis.
  • Both the WHO (2022) and India's National Tuberculosis Elimination Program (NTEP 2024) have adopted the 4-month regimen as the standard of care for non-severe pediatric TB.

The Landmark SHINE Trial (NEJM 2022)

  • Study Citation: Turkova et al., Shorter Treatment for Minimal Tuberculosis in Children (SHINE), New England Journal of Medicine, March 2022.
  • Design: Open-label, randomized, controlled, phase 3 non-inferiority trial across 4 countries (South Africa, Uganda, Zambia, and India) enrolling 1,204 children aged 2 months to 16 years.
  • Intervention: 4-month regimen (8 weeks of daily 2HRZ $\pm$ E followed by 8 weeks of 2HR) vs Standard 6-month regimen (8 weeks 2HRZ $\pm$ E followed by 16 weeks of 4HR).
  • Primary Endpoint: Unfavorable outcome (treatment failure, recurrence, loss to follow-up, or death) at 72 weeks.
  • Landmark Findings:
    • Unfavorable outcome occurred in $3\%$ of children in the 4-month arm vs $3\%$ in the 6-month arm (adjusted difference $-0.4\%$; $95\%\text{ CI: } -2.2\text{ to }1.5\%$).
    • Met the pre-specified non-inferiority margin (within $6\%$).
    • Results were consistent across HIV-infected and HIV-uninfected children.
    • Significant reduction in treatment burden: eliminated 60 daily doses of ATT per child without compromising cure.

Defining "Non-Severe" vs. "Severe" Pediatric TB

Accurate clinical and radiological staging is paramount; severe forms must receive the standard 6 to 12-month course.

flowchart TD
    A["Child (3 months to 16 years) with Presumptive / Confirmed TB"] --> B["<b>Comprehensive Staging & Chest Radiography</b><br>Assess Smear status, CXR extent, Extrapulmonary sites"]
    
    B --> C{"Severe Criteria Present?"}
    
    C -->|"Yes (Any of the following)"| D["<b>Severe TB: Standard 6–12 Month Regimen</b><br>• Cavitary lesions on CXR<br>• Bilateral extensive infiltrate or > 1 whole lobe involved<br>• Miliary TB / Disseminated TB<br>• CNS TB / Meningitis (12 months)<br>• Osteoarticular / Pott's spine (9–12 months)<br>• Smear-positive for AFB<br>• Severe acute malnutrition (SAM)"]
    
    C -->|"No (Meets Non-Severe Criteria)"| E["<b>Non-Severe TB: 4-Month Regimen (SHINE)</b><br>• Intrathoracic lymphadenopathy without airway obstruction<br>• Uncomplicated pulmonary infiltrates confined to ≤ 1 lobe<br>• Peripheral lymph node TB (scrofula without fistulization)<br>• Smear-negative (gastric aspirate / induced sputum)<br>• Non-severe CXR pattern"]
    
    E --> F["<b>2HRZ / 2HR (Total 16 Weeks)</b><br>Dispersible child-friendly FDC tablets"]

Drug Regimen And Dosing Breakdown

Regimen Architecture: 2HRZ(E) / 2HR

  • Intensive Phase (8 Weeks / 2 Months): Daily Isoniazid (H) + Rifampicin (R) + Pyrazinamide (Z) $\pm$ Ethambutol (E).
  • Continuation Phase (8 Weeks / 2 Months): Daily Isoniazid (H) + Rifampicin (R).
  • Ethambutol inclusion: Added in areas with high background INH resistance or in HIV co-infection.

WHO & NTEP Weight-Band Dosing (Dispersible FDCs)

Children metabolize anti-TB drugs more rapidly than adults, requiring higher mg/kg doses:

  • Isoniazid (H): $10\text{ mg/kg/day}$ (range $7–15\text{ mg/kg}$).
  • Rifampicin (R): $15\text{ mg/kg/day}$ (range $10–20\text{ mg/kg}$).
  • Pyrazinamide (Z): $35\text{ mg/kg/day}$ (range $30–40\text{ mg/kg}$).
  • Ethambutol (E): $20\text{ mg/kg/day}$ (range $15–25\text{ mg/kg}$).

Administered using child-friendly fruit-flavored dispersible FDC tablets:

  • 3-FDC (HRZ 50/75/150 mg) for intensive phase.
  • 2-FDC (HR 50/75 mg) for continuation phase.

Programmatic And Clinical Advantages

  1. Adherence Enhancement: Truncating therapy by two full months prevents late treatment dropouts, which typically spike between months 4 and 6.
  2. Reduced Hepatotoxicity: Drug-induced liver injury (DILI) risk compounds with duration; shortening continuation therapy lowers cumulative exposure.
  3. Cost and Logistics: Lowers supply chain procurement expenditure by $>30\%$, enabling NTEP to redirect resources toward active case-finding.
  4. Antimicrobial Stewardship: Limits collateral disruption of the developing pediatric gut microbiome and reduces selection pressure for resistant flora.